Protego Bio

Protego Biopharma is a biotechnology startup that is pioneering the discovery and development of innovative therapeutics to treat protein misfolding diseases. The company operates in the pharmaceutical industry, specifically in the drug discovery sector. Its primary focus is on systemic amyloid diseases like light chain (LC) amyloidosis and other monogenetic protein misfolding diseases that cause a variety of health issues including myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases.

Protego Biopharma's business model revolves around the use of advanced bioinformatics, deep biology, and clinical path analysis to identify high-confidence targets for drug development. The company's approach is data-driven and focuses on modifying diseases through an innovative discovery platform. They also use specific and sensitive biomarkers for early patient identification and to measure therapeutic efficacy.

The company's revenue model is likely based on the development and commercialization of its therapeutics. Once a drug is developed, it can be patented and sold to healthcare providers or directly to patients. Additionally, the company may generate income through partnerships or collaborations with other pharmaceutical companies.

The company was co-founded by Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, who have previously demonstrated success in this field with the discovery and development of tafamidis, a drug used for the treatment of transthyretin amyloidosis.

Keywords: Biotechnology, Drug Discovery, Protein Misfolding Diseases, Systemic Amyloid Diseases, Bioinformatics, Disease Modifying, Biomarker Discovery, Precision Medicine, Pharmacological Chaperones, Therapeutics.